EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Earlier Initiation of Immunosuppression

Mohammad Ma'koseh, Zaid Abdel Rahman, Abeer Yaseen, Ahmad Mesmar, Husam Abu-Jazar, Salwa Saadeh, Duaa Mufarrej, Rozan Alfar, Waleed Da'na, Khalid Halahleh, Hasan Hashem, Akram Al-Ibraheem und 2 weitere

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.01.023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Mohammad Ma'koseh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan; School of Medicine, The University of Jordan, Amman, Jordan. Electronic a…. Hauptthemen laut MEDLINE: Cyclophosphamide, Transplantation, Haploidentical, Peripheral Blood Stem Cell Transplantation, Hematologic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: King Hussein Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Peripheral blood (PB) grafts are increasingly used in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PT-Cy). The optimal timing for initiation of immunosuppression (IS) with calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) in PB haplo-HSCT is unclear. This study evaluates the outcomes of early initiation of IS prior to PT-Cy. METHODS: Medical records of adult patients with hematologic malignancies who received PB haplo-HSCT with PT-Cy between 2017 and 2022 were retrospectively reviewed. IS with CNI and MMF were started on day 0 and 1 postinfusion. Statistical analyses for survival outcomes were performed using the Kaplan-Meier method, and cumulative incidence (CI) models were used to account for competing risks for relapse, and nonrelapse mortality (NRM). RESULTS: A total of 51 patients were included, with a median age of 37 years (range: 19-63) and a median follow-up of 44 months (range: 37.8-53 months). Neutrophil and platelet engraftment were achieved in 98% and 96% of patients, respectively. CRS occurred in 35.3% of patients, predominantly grade I, with only 1 patient developing grade II CRS. At 3 years, overall survival (OS) and progression free survival (PFS) were 51.8% and 50.2%, respectively, and GVHD-relapse free survival (GFRS) was 43.1%. The CI of relapse and NRM at 3 years were 28.2% and 21.6%, respectively. CONCLUSION: Early initiation of IS in PB haplo-HSCT was associated with high rates of engraftment, low rates of CRS, and favorable long-term survival outcomes. Prospective studies are needed to validate these findings and refine IS timing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideTransplantation, HaploidenticalPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsImmunosuppressive AgentsImmunosuppression TherapyHumansFemaleAdultMaleMiddle AgedRetrospective StudiesYoung AdultTreatment OutcomeGraft vs Host Disease

Stichwörter der Autor:innen

GVHDHaploidentical HSCTImmunosuppressionRelapseSurvival

Substanzen

CyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan; School of Medicine, The University of Jordan, Amman, Jordan. Electronic address: mm.09744@khcc.jo.
  • Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan; School of Medicine, The University of Jordan, Amman, Jordan.
  • Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
  • Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan.
  • Department of Pediatric, King Hussein Cancer Center, Amman, Jordan.
  • Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.

Förderung

  • King Hussein Cancer Center

Zitieren

APA

Ma'koseh, M., Rahman, Z. A., Yaseen, A., Mesmar, A., Abu-Jazar, H., Saadeh, S., Mufarrej, D., Alfar, R., Da'na, W., Halahleh, K., Hashem, H., Al-Ibraheem, A., Al-Rabi, K., & Abdel-Razeq, H. (2025). Outcomes of Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Earlier Initiation of Immunosuppression. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.01.023

Vancouver

Ma'koseh M, Rahman ZA, Yaseen A, Mesmar A, Abu-Jazar H, Saadeh S, et al. Outcomes of Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Earlier Initiation of Immunosuppression. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.01.023

BibTeX
@article{Makoseh2025,
  author = {Ma'koseh, Mohammad and Rahman, Zaid Abdel and Yaseen, Abeer and Mesmar, Ahmad and Abu-Jazar, Husam and Saadeh, Salwa and Mufarrej, Duaa and Alfar, Rozan and Da'na, Waleed and Halahleh, Khalid and Hashem, Hasan and Al-Ibraheem, Akram and Al-Rabi, Kamal and Abdel-Razeq, Hikmat},
  title = {Outcomes of Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Earlier Initiation of Immunosuppression},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.01.023}
}
Kostenlos starten →